Activation of Peroxisome Proliferator-activated Receptor γ Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt-β-catenin Signaling as a Possible Mechanism

Journal of Cardiovascular Pharmacology

Volumn 68, Issue 2, 2016, Pages 155-161

  Kamimura, Daisuke ^a,b   Uchino, Kazuaki ^b   Ishigami, Tomoaki ^b   Hall, Michael E ^a   Umemura, Satoshi ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

diastole; fibrosis; heart failure; PPAR ; Wnt catenin

Indexed keywords

BETA CATENIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; SODIUM CHLORIDE; WNT1 PROTEIN; WNT10B PROTEIN; WNT2 PROTEIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CTNNB1 PROTEIN, RAT; PPAR GAMMA, RAT; SALT INTAKE; WNT PROTEIN; WNT1 PROTEIN, RAT; WNT10B PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE LENGTH; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DRUG MECHANISM; GENE EXPRESSION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE RELAXATION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RATE; LUNG WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; TIBIA; WNT SIGNALING PATHWAY; AGONISTS; ANIMAL; DAHL RAT; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENETICS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; HEART VENTRICLE REMODELING; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; SALT INTAKE; TIME FACTOR; WNT SIGNALING;

ANIMALS; BETA CATENIN; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROSIS; HEART FAILURE; HEART VENTRICLES; HYPERTENSION; MALE; PPAR GAMMA; RATS, INBRED DAHL; RNA, MESSENGER; SODIUM CHLORIDE, DIETARY; STROKE VOLUME; THIAZOLIDINEDIONES; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING; WNT PROTEINS; WNT SIGNALING PATHWAY; WNT1 PROTEIN; WNT2 PROTEIN;

EID: 84962361589     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000397     Document Type: Article

References (38)

1. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
2. Zile MR, Baicu CF, Ikonomidis JS, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247-1259.
3. Zafiriou S, Stanners SR, Saad S, et al. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol. 2005;16:638-645.
4. Omasu F, Oda T, Yamada M, et al. Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats. Am J Physiol Ren Physiol. 2007;293: F1292-F1298.
5. Barbarin V, Nihoul A, Misson P, et al. The role of pro- and antiinflammatory responses in silica-induced lung fibrosis. Respir Res. 2005;6:112.
6. Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 2002;122:1924-1940.
7. Elrashidy RA, Asker ME, Mohamed HE. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012;17:324-333.
8. Caglayan E, Stauber B, Collins AR, et al. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes. 2008;57:2470-2479.
9. Terui G, Goto T, Katsuta M, et al. Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients. J Cardiol. 2009;54:52-58.
10. Surendran K, Schiavi S, Hruska KA. Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol. 2005;16:2373-2384.
11. Cheng JH, She H, Han YP, et al. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2008;294:G39-G49.
12. Konigshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest. 2009;119: 772-787.
13. Naito AT, Shiojima I, Komuro I. Wnt signaling and aging-related heart disorders. Circ Res. 2010;107:1295-1303.
14. Jansson EA, Are A, Greicius G, et al. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. Proc Natl Acad Sci U S A. 2005;102:1460-1465.
15. Lu D, Carson DA. Repression of beta-catenin signaling by PPAR gamma ligands. Eur J Pharmacol. 2010;636:198-202.
16. Takada I, Mihara M, Suzawa M, et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol. 2007;9:1273-1285.
17. Moldes M, Zuo Y, Morrison RF, et al. Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis. Biochem J. 2003;376:607-613.
18. Masuyama T, Yamamoto K, Sakata Y, et al. Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol. 2000;36:2333-2338.
19. Kato MF, Shibata R, Obata K, et al. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J Hypertens. 2008;26:1669-1676.
20. Maeda A, Tamura K, Wakui H, et al. Effects of the Angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disorders. Biomed Res Int. 2014;2014:946492.
21. Kamimura D, Ohtani T, Sakata Y, et al. Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction. Eur Heart J. 2012;33:1408-1416.
22. Sakata Y, Masuyama T, Yamamoto K, et al. Renin angiotensin systemdependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol. 2001;37:293-299.
23. Diez J, Querejeta R, Lopez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512-2517.
24. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781.
25. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27:2338-2345.
26. He W, Dai C, Li Y, et al. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol. 2009;20:765-776.
27. Chen JH, Chen WL, Sider KL, et al. beta-catenin mediates mechanically regulated, transforming growth factor-beta1-induced myofibroblast differentiation of aortic valve interstitial cells. Arterioscler Thromb Vasc Biol. 2011;31:590-597.
28. Sakata Y, Yamamoto K, Masuyama T, et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens. 2001;19:1905-1912.
29. Liu J, Wang H, Zuo Y, et al. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol 2006;26:5827-5837.
30. Lu D, Cottam HB, Corr M, et al. Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2005;102:18567-18571.
31. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26:2493-2499.
32. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000;101:899-907.
33. Samuelsson AM, Bollano E, Mobini R, et al. Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. Am J Physiol Heart Circ Physiol. 2006;291:H787-H796.
34. Zhou MS, Liu C, Tian R, et al. Skeletal muscle insulin resistance in saltsensitive hypertension: role of angiotensin II activation of NFkappaB. Cardiovasc Diabetol. 2015;14:45.
35. Friedmann PS, Cooper HL, Healy E. Peroxisome proliferator-activated receptors and their relevance to dermatology. Acta Derm Venereol. 2005; 85:194-202.
36. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
37. van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009;119:2069-2077.
38. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30:2773-2778.